Ann Lee - Jan 3, 2022 Form 4 Insider Report for Coya Therapeutics, Inc. (COYA)

Role: Director
Signature: /s/ David Snyder, Attorney-in-Fact
Stock symbol: COYA
Transactions as of: Jan 3, 2022
Transactions value $: $916
Form type: 4
Date filed: 1/4/2023, 07:30 AM
Next filing: Dec 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	COYA	Common Stock, par value $0.0001 per share	Purchase		+10K			10K	Jan 3, 2023	Direct	F1
transaction	COYA	Common Stock, par value $0.0001 per share	Conversion of derivative security	$25.9K	+6.48K	+64.79%	$4.00	16.5K	Jan 3, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COYA	Warrant to Purchase Common Stock	Purchase		+5K	+111.63%		9.48K	Jan 3, 2023	Common Stock, par value $0.0001 per share	5K	$7.50	Direct	F1
transaction	COYA	6% Convertible Note	Conversion of derivative security	-$25K				6.48K	Jan 3, 2023	Common Stock, par value $0.0001 per share	6.48K	$4.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reporting Person purchased 10,000 shares of Common Stock and accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering ("IPO") at a combined purchase price $5.00 per share and accompanying warrant.
F2	Upon the closing of the Issuer's IPO, the Convertible Note automatically converted into shares of common stock by dividing the then-outstanding principal and interest due under the Convertible Note by $4.00, or 80% of the IPO price. The Reporting Person held a Convertible Note for $25,000 that accrued interest at 6% per annum.